Notice of Extraordinary General Meeting
To the shareholders of ORIGIO a/s Notice is hereby given of an extraordinary general meeting of ORIGIO a/s to be held on:
Friday, 10 August 2012 at 1 pm
at Plesner law firm,
Amerika Plads 37,
DK-2100 København Ø
The agenda of the meeting is as follows:
- Election of new members of the board of directors
- Delegation of authority to the board of directors to apply for delisting of ORIGIO a/s from the Oslo Stock Exchange
- Delegation of authority to the chairman of the general meeting
Registration form and proxy have been sent to the shareholders. Registration to attend the Extraordinary General Meeting can be made by returning the registration form (Møteseddel) to DNB Bank ASA, Verdipapirservice, 0021 Oslo, or by faxing it to fax number +47 22 48 11 71, or alternatively by electronic registration at VPS Investortjenester or www.origio.com by 23.59 o’clock on August 6, 2012.
Please note that CooperVision International Holding Company, LP's acquisition of more than 96% of the shares of ORIGIO a/s will be completed at the latest by 13 July 2012 which is the latest settlement date in relation to the selling shareholders.
Please find attached the full Notice of Extraordinary General Meeting.
For further information, please contact:
Flemming Pedersen, Chairman: +45 2148 0118
or email: email@example.com
Jesper Funding Andersen, CEO: +45 4073 0963
or email: firstname.lastname@example.org
About ORIGIO a/s
ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to ART professionals to help the #1 dream of every infertile couple come true. ORIGIO currently comprises the five product families, MediCult Media, Humagen Pipets, MidAtlantic Devices, ORIGIO ScanLab Equipment and Artworks Solutions that cater for the broadest range of ART requirements. The medtech company ORIGIO, which is headquartered in Måløv, Denmark, and has subsidiaries in 12 countries, is listed on the Oslo Stock Exchange under the symbol, ORO. For further information, please visit www.origio.com.
About Cooper Companies, Inc.
The Cooper Companies, Inc. is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 7,000 employees with products sold in over 100 countries. For more information, please visit
Certain statements in this announcement contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this announcement will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO’s anticipated schedule. These factors, and other factors including, but not limited to, those described in ORIGIO’s most recent annual report, could cause future results to differ materially from the expectations expressed in this announcement. The forward-looking statements contained in this announcement may become outdated over time. ORIGIO does not assume any responsibility for updating any forward-looking statements.